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Objective: Although reduced amplitude of the P300 event-related potential is a well-documented intermediate
phenotype of schizophrenia, little is known about its genetic underpinnings in patients with schizophrenia. This
study aims to examine associations between P300 and a range of candidate genetic variants, selected from either
candidate gene studies or genome-wide association studies, in a large sample of patients with schizophrenia.
Methods: P300 amplitude at themidline parietal electrode and 193 single nucleotide polymorphisms (SNPs) in 67
genes were assessed in 336 patients with schizophrenia. The association between each SNP and P300 amplitude,
controlled for illness duration and gender, was evaluated. Associations at pb .01 were considered of potential rel-
evance, while Bonferroni correctionwas applied to determine formal statistical significance (Bonferroni-corrected
threshold of significance p=.0003).
Results: Of the 193 selected SNPs, 4 SNPs showed potentially relevant association with P300 amplitude at a signifi-
cance level of pb .01. One of these SNPs, rs1045642 in ABCB1, was most convincingly associated with P300 ampli-
tude, reaching formal (Bonferroni-corrected) significance, while there was evidence for possible association with
rs1572899 in DISC-1, rs6265 in BDNF and rs1625579 in MIR137.
Conclusion:Genetic variation in ABCB1may be associated with P300 amplitude in patients with schizophrenia. This
result may encourage further efforts to elucidate the genetic underpinnings of P300 generation.© 2012 Elsevier B.V. All rights reserved.1. Introduction
The auditory P300 is an event-related potential (ERP) that is typically
elicited by an auditory target stimulus serving as the signal for the partic-
ipant to execute a predefined task, such as pushing a button or counting.
It is named after its typical peak 300 ms after the target stimulus. The
P300 is believed to reflect a summation of simultaneous brain processes,
including directed attention and contextual updating of workingmemo-
ry (Turetsky et al., 2007; vander Stelt and Belger, 2007). It is described by
its amplitude and latency. Two subcomponents can be distinguished: the
P3a subcomponent with a predominantly frontal distribution, which re-
flects the unexpectedness of the stimulus and the P3b subcomponent
with a predominantly parietal distribution, reflecting cognitive process-
ing of task-relevant or contextually salient stimuli (Turetsky et al., 2007).
Reduced amplitude of the auditory P300, especially the P3b
subcomponent, has been consistently reported in patients with schizo-
phrenia (Turetsky et al., 2007; van der Stelt and Belger, 2007). Although
reduced P300 amplitude is not specific to schizophrenia, the observed
deficits are distinguishable in several aspects from the P300-deficits iny and Psychology, Maastricht
N2), 6200 MD Maastricht, The
8 689.
ty.nl (R. van Winkel).
rights reserved.Alzheimer disease (marked latency prolongation), alcoholism (more
visual than auditory abnormalities) and depression (state-dependent
abnormalities), suggesting different underlying neural mechanisms
(Souza et al., 1995; Salisbury et al., 1999; Turetsky et al., 2007). Howev-
er, since P300 amplitudes at centro-parietal sites in patients with bipo-
lar disorder manifesting psychotic symptoms were not distinguishable
from those of patients with schizophrenia, it was suggested that de-
creased P300 amplitude at these sites may mark functional psychosis
in general (Bestelmeyer et al., 2009).
The heritability of the P300 was established by several twin studies
(O'Connor et al., 1994; Bestelmeyer et al., 2009; Hall et al., 2009). More-
over, part of the genetic contribution to the P300 waveform is shared
with the genetic contribution to schizophrenia (Hall et al., 2007) and
family members of patients with schizophrenia also show significantly
reduced P300 amplitudes compared to the general population,
although to a lesser degree than their ill relatives (Bramon et al., 2005).
Reduced P300 amplitude was found in first-episode patients, recent-
onset, chronic patients and even people at ultra-high risk for psychosis
(van Beijsterveldt et al., 2001; Umbricht et al., 2006; Turetsky et al.,
2007; van der Stelt and Belger, 2007; van Tricht et al., 2011). Given
these findings, a decrease in the amplitude of the P300 is commonly
accepted as an intermediate phenotype for schizophrenia (Turetsky et
al., 2007; van der Stelt and Belger, 2007).
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intermediate phenotype for schizophrenia, there is limited knowledge
of the actual genetic underpinnings of P300 generation in general, and
P300 disruption in schizophrenia specifically (Turetsky et al., 2007; van
der Stelt and Belger, 2007). Blackwood et al. (2001) reported a reduction
of P300 amplitude in a large Scottish familymultiply affectedwith schizo-
phrenia. In this family, a balanced translocation of chromosome 1 and 11,
disrupting the DISC1 gene, was strongly associated with both the diagno-
sis of schizophrenia and reduced P300 amplitude (Blackwood et al.,
2001). In addition, reduced P300 amplitude was also observed in unaf-
fected carriers of the translocation (Blackwood et al., 2001). Further stud-
ies used a candidate gene approach to examine the associationwith P300
amplitude in healthy controls (Tsai et al., 2003a; Tsai et al., 2003b;Mulert
et al., 2006; Vogel et al., 2006; Gallinat et al., 2007; Schofield et al., 2009;
Shaikh et al., 2011), patients with a diagnosis of depression (Chen et al.,
2002) or addiction (Johnson et al., 1997; Hill et al., 1998; Berman et al.,
2006; Antolin et al., 2009), as well as patients with schizophrenia
(Gallinat et al., 2003; Bramon et al., 2006; Golimbet et al., 2006; Bramon
et al., 2008; Wang et al., 2009; Shaikh et al., 2011). These studies com-
monly focused on a single gene, often even limited to a single nucleotide
polymorphism (SNP). This is potentially problematic since there are in-
creasing concerns about the candidate gene approach, as the high preva-
lence of false-positive findings in genetic research may not always be
adequately taken into account, especially in the context of undisclosed
multiple statistical comparisons (Sullivan, 2007). On the other hand, sam-
ple sizes are often too small to allow for the use of genome-wide chips,
suggesting that a candidate gene approach with a larger number of
SNPs andadequate control formultiple testingmaybe themost viable op-
tion for the research of candidate endophenotypes (Greenwood et al.,
2011). Therefore, the current study examined a range of candidate
SNPs, selected from either candidate gene studies or genome-wide asso-
ciation studies, in a sample of 336 patientswith a schizophrenia spectrum
disorder.
2. Materials and methods
2.1. Subjects
The sample of this study was recruited between October 1999 and
November 2006. Psychiatric diagnoses according to DSM-IV criteria
were established by experienced psychiatrists affiliated with the Uni-
versity Centre at Louvain, Belgium, and responsible for the patient's
treatment. In the University Centre, P300 analysis forms part of a com-
prehensive neurological and neurophysiological assessment conducted
in inpatients, after clinical stabilization. Conform to international guide-
lines (De Hert et al., 2009), patients receive an elaborate physical health
screening including assessment of fasting glucose, lipids and other pa-
rameters as described previously (van Winkel et al., 2006; De Hert et
al., 2010). On this occasion, they were asked for permission to store a
blood sample for genetic analyses and for the anonymous analysis of
clinical data recorded during their treatment. The study was approved
by the standing ethics committee.
2.2. P300-recording
P300 datawere recorded using aNeurofax Portable Electroencephalo-
graph EEG-7414 (Nihon Kohden Corporation, Tokyo). During the record-
ing patients were seated in a slightly reclined chair and were asked to fix
their gaze at a mark approximately 1 meter in front of them. Evoked
responseswere recordedwith 3mid-line electrodes (Fz, Cz and Pz), posi-
tioned according to the international 10/20 system and online referenced
to left and right ear-electrodes (A1 and A2). Electro-oculogram (EOG)
was recorded in order to reject P300-epochs distorted by eye-
movement artefacts. All electrodes were attached with a skin-electrode
impedance of less than 5 kOhm.120 sinus tones of 800 Hz (standard) and 30 sinusoidal tones of
1470 Hz (deviant), both with a duration of 40 ms and an intensity of
70 dB sound pressure level, were presented binaurally through
earphones. Each inter-stimulus interval (ISI) was 1 s. Standard and devi-
ant tones were mixed randomly. Patients were asked to push a button as
quickly as possiblewhenhearing a deviant tone. Datawere collectedwith
a sampling rate of 1024 Hz and with a high cut-off at 70 Hz. The
event-related potentials (ERP) elicited by correctly processed standard
(without push on button) and deviant tones (push on button)were aver-
aged separately for each subject, using the EEG epochs from 100 ms
pre-stimulus to 600 ms post-stimulus. The obtained curves (Fz, Cz, Pz
and EOG) were displayed on a LCD-screen and for each electrode the
N100 and P300 peaks after the deviant tone were manually indicated.
The most negative deflection between 50 ms and 150 ms post-stimulus
was considered as the N100, the most positive deflection between
250 ms and 400 ms as the P300. The obtained curves and the indicated
peak valueswere printed and the paper report was stored in the patient's
file. For 336 patients both DNA and P300 data were available. Because a
reduction of P300 amplitude over the midline parietal electrode Pz was
described as a very robust finding in patients with schizophrenia
(Turetsky et al., 2007; van der Stelt and Belger, 2007), P300 amplitude
at Pz was a priori used for all analyses. During the retrieval of the
P300-data, the printed curves were visually inspected. The amplitude of
the averaged EOG-curves exceeded the amplitude of the P300-waves in
145 patients. Although EOG-artefacts are not expected to affect measure-
ments at Pz, analysis of the entire sample of 336 patients was
complemented with a sensitivity analysis in the sample of 191 patients
for whom the averaged EOG curves did not exceed the P300 amplitude.
2.3. Genetic variation
A previous study of our group, which examined molecular-genetic
interactions with cannabis, selected a total of 179 SNPs, 152 of which
passed quality control and were subsequently analyzed (van Winkel
and GROUP Investigators, 2011). Gene selection in this study was based
on previous evidence of association with schizophrenia, involvement in
dopamine or endocannabinoid signaling or an involvement in the regula-
tion of environmental influences including epigenetic mechanisms. Since
this selection included the most studied candidate genes for schizophre-
nia prior to the genome-wide studies, this set was used as the starting
point for our SNP selection. This set was updated with 24 SNPs either
showing association with schizophrenia at grade ‘A’ or ‘B’ level in the
SzGene database (Allen et al., 2008) (update 26 February 2010) or identi-
fied by genome-wide association studies (situated in PGBD1, NRGN,
NOTCH4, PDE4B, TCF4, TPH1, HTR2A, RELN, MDGA1, CCKAR, DRD4,
APOE, GWAS 11p14.1, PLXNA2, GABRB2, SRR, ANK3, CACNA1C,
ZNF804A, MHC, MIR137). Finally, a set of 10 SNPs was selected for
intended pharmacogenetic studies (in ABCB1, ADH1C, AS3MT,
CYP17A1, CYP1A2, CYP2D6, FOXA2, GSTP1, SOD2). It was decided to
also analyze these SNPs in the context of this study, since for one of
these SNPs, rs1045642 in ABCB1, an association with P300-amplitude
was found in a sample of healthy controls using a data-driven analysis
with 384 SNPs in 222 genes, which survived stringent correction formul-
tiple testing (Liu et al., 2009).
The sample used in this article is completely independent of the
GROUP sample that was used to examine the molecular-genetic interac-
tions with cannabis (van Winkel and GROUP Investigators, 2011). The
sample analyzed here is part of a larger sample (UPC-CUL sample) previ-
ously described in the context of metabolic syndrome (van Winkel et al.,
2010), which now has been genotyped for the same markers as the
GROUP sample with the intention of replication of the molecular-
genetic cannabis findings. From the UPC-CUL sample, only the patients
for whom a P300 measurement was available (n=336) were included
in this current study.
The selected SNPs were determined by Sequenom (Hamburg,
Germany) using the MassARRAY iPLEX platform at the facilities of
Table 1
Epidemiological and clinical information of the total sample and the sensitivity analysis
subsample.
Total sample Sensitivity analysis pa
(n=332) (n=190)
Male (%) 230 (68.5%) 142 (74.4%) .010
Mean age (SD) 32.4 (11.0) 31.3 (10.2) .030
Age range 14.4–64.2 14.4–57.1
DSM-IV diagnosis .039
Schizophrenia 216 (64.3%) 128 (67.0%)
Schizophreniform disorder 41 (12.2%) 16 (8.4%)
Schizo-affective disorder 79 (23.5%) 47 (24.6%)
Illness duration in years (SD) 8.5 (9.6) 7.6 (8.8) .092
Antipsychotic medication b
Fenothiazines 22 (8.8%) 11 (8.1%) .776
Thioxanthenes 46 (18.47%) 24 (17.7%) .633
Butyrophenones 28 (11.2%) 21 (15.4%) .026
Diphenylbutylpiperidine 2 (0.8%) 1 (0.7%) .879
Amisulpride 22 (8.8%) 14 (10.3%) .411
Aripiprazole 5 (2.0 %) 1 (0.7%) .219
Clozapine 25 (10.0%) 13 (9.6%) .724
olanzapine 76 (30.5%) 43 (31.6%) .888
Quetiapine 27 (10.8%) 13 (9.6%) .724
Risperidone 88 (36.1%) 49 (36.0%) .933
Cannabis use .489
Non-user 196 (59.2%) 110 (57.9%)
User, outside heaviest period 115 (34.7%) 66 (34.7%)
User, during heaviest period 20 (6.0%) 14 (7.3%)
CGI (SD) 4.3 (0.8) 4.1 (0.7) b .001
GAF (SD) 57.6 (11.1) 60.0 (9.0) b .001
Chi-squared test for categorical variables, double-sided paired t-test for continuous
variables.
SD=standard deviation/CGI=clinical global impression (scale form 1–7)/GAF=global
assessment of functioning.
a p‐Values of statistical comparison between patients in sensitivity analyses and those
who were dropped on the basis of EOG artefacts.
b Data available for 249 patients (74.1%) of the total sample, ofwhom136 (71.2%) in the
sensitivity analysis.
56 J. Decoster et al. / Schizophrenia Research 141 (2012) 54–59the manufacturer; SNPs, therefore, were not selected from a larger set
of genomewide markers.
Of the 205 SNPs originally included, (see Supplementary Table S1),
8 SNPswere excluded because they hadmore than 10% genotyping fail-
ure (rs165599 in COMT, rs1800955 in DRD4, rs2032582 in ABCB1,
rs265981 in DRD1, rs3892097 in CYP2D6, rs403636 in SLC6A3,
rs6465084 in GRM3 and rs9296158 in FKBP5). 3 SNPs were excluded
because of Hardy–Weinberg disequilibrium (pb .001) (rs2023239 in
CNR1, rs28362317 in SLC6A3 and rs743572 in CYP17A1) and no varia-
tion was found for 1 SNP (rs1799961 in DRD1). Thus, a final set of 193
SNPs in 67 genes was suitable for further analysis.
2.4. Statistical analyses
All analyses were conducted using STATA/SE 10.1 for Windows
(StataCorp, 2007), regressing continuous P300 amplitude, as dependent
variable, on each SNP. Genotypes were coded ‘0’, ‘1’ or ‘2’ according to
the number of minor alleles and modeled as a linear effect, since this
method candealwithdifferent genotypedistributions, includingdistribu-
tions with a low minor allele frequency, as it avoids stratification into
small subgroups (Cordell and Clayton, 2005). Given the amount of multi-
ple testing involved, associations at pb .01 were arbitrarily considered of
potential relevance,while Bonferroni correctionwas applied todetermine
formal statistical significance (Bonferroni-corrected threshold of signifi-
cance p=.0003). Thus, SNPs that reached pb .01 significance in the
main analysis were also analyzed in the sample of 191 patients with a
P300measurement surpassing themost stringent quality control as a sen-
sitivity analysis to maximize the signal to noise ratio, however at the cost
of reduced statistical power. All P300 values differing more than 3 stan-
dard deviations from themeanwere considered as outliers and excluded
from the regression analyses (n=4 in themain analysis, n=1 in the sen-
sitivity analysis), as recommended byOsborne andOverbay (2004). Anal-
yses were controlled for the a priori defined confounders illness duration
and gender.
A statistical power calculation was performed for the total sample as
well as for the sensitivity analysis. In the total sample, this study has a
power of 100% to detect a SNP that explains 10% of the variation in
P300 amplitude according to the used regression model (with α=.01),
95% to detect a SNP accounting for 5% and 53% to detect a SNP accounting
for 2% of the P300 variation. In the sensitivity analyses, the power de-
creases to 98%, 74% and 29%, respectively.
3. Results
3.1. Sample
The sample consisted of 336 individuals with a psychotic disorder
who were on average 32.6 years old (SD 11.0, range 14.4–64.2) and of
whom 68.5% were male. The average illness duration was 8.5 year (SD
9.6, range 0–42). Patients had clinical diagnoses of schizophrenia
(64.3%), schizophreniform disorder (12.2%) or schizoaffective disorder
(23.5%). For the sensitivity analysis, 191 individuals were included with
an average age of 31.3 years (SD 10.2, range 14.4–57.1), 74.4% were
male. The average illness duration was 7.6 year (SD 8.8, range 0–34),
also with clinical diagnoses of schizophrenia (67.0%), schizophreniform
disorder (8.4%) or schizoaffective disorder (24.6%) (see Table 1 for
more details). Because of the significant differences in diagnosis, Clinical
Global Impression (CGI) scale and Global Assessment of Functioning
(GAF) score, those three variables were added as possible confounders
in the regression model of the sensitivity analysis.
3.2. P300
The overall mean P300 amplitude at Pz was 13.2 μV (SD 6.4;
range − .4 to 48.8). Four outliers were excluded from the analyses,
resulting in a corrected average of 12.9 μV (SD 5.6; range − .4 to32.4). P300 amplitudewas significantly associatedwith illness duration
(Coef=− .107; 95%-CI:− .170 to− .044; p=.001), but notwith gender
(Coef=− .478; 95%-CI: −1.794 to .837; p=.475). Four SNPs showed
an association with P300 amplitude at pb .01; situated in ABCB1,
MIR137, BDNF and DISC-1 (Table 2). The sensitivity analysis supported
an association with P300 amplitude for rs1045642 in ABCB1 (reaching
Bonferroni-corrected statistical significance), and to a lesser degree for
rs1572899 in DISC-1 and for rs6265 in BDNF, but not for rs1625579 in
MIR137 (Table 2). Patients homozygous for the C-allele of rs1045642
(n=76) had an average P300 amplitude of 11.4 μV (SD 5.1 μV) versus
12.8 μV (SD 5.8 μV) in heterozygous patients (n=167) and 14.4 μV
(SD 5.6 μV) in patients with the T/T genotype (n=89) (Fig. 1). A
QQ-plot of the residuals of the regressionmodel indicated no departure
from normality.
3.3. Follow-up analyses of the ABCB1 finding
The ABCB1-gene, formerly called Multi Drug Resistance 1 (MDR1)
gene, encodes for the P-glycoprotein that has a known function in
ATP-driven cellular excretion of a wide range of exogenous and endog-
enous substrates, like drugs, hormones (Moons et al., 2011) and tetra-
hydrocannabinol (THC) (Bonhomme-Faivre et al., 2008). Therefore,
post-hoc analyses examined possible confounding of the association be-
tween P300 and ABCB1 by antipsychotic medication and cannabis use.
None of the different classes of antipsychoticswas significantly asso-
ciated with P300 amplitude (Table 3). Moreover, when covarying for
type of antipsychotic, the association between rs1045642 in
ABCB1 and P300 amplitude remained significant (Coef=−1.822;
95%-CI: −2.826 to− .818; p=.00042).
Lifetime cannabis use was assessed using the Composite Inter-
national Diagnostic Interview (CIDI)-lifetime section on substance
Table 2
Regression model of P300 amplitude, controlled for illness duration and sex in the main analysis, with 3 additional confounders in the sensitivity analysis; diagnosis, CGI and
GAF-score. A positive coefficient (coef) reflects an association of higher P300 peak amplitude with the minor allele, a negative coefficient reflects an association with the major
allele. Results of SNPs with p-valueb .01 in the main analysis are displayed, as well as the coefficient and p-value in the sensitivity analysis. The percentage of P300 variation
explained (EV) by adding the SNP in the significant models, is also reported.
SNP gene coef main analysis 95%-confidence interval p-value main analysis EV, % coef sensitivity analysis p-value sensitivity analysis EV, %
rs1045642 ABCB1 −1.37 −2.15 to −0.59 0.0021 2.9 −2.01 0.00017 7.0
rs1625579 MIR137 1.70 .52–2.88 0.0048 2.0 .91 0.2215
rs6265 BDNF −1.47 −2.53 to −0.41 0.0068 2.6 −1.61 0.0265 2.5
rs1572899 DISC-1 −1.26 −2.19 to −0.34 0.0076 2.2 −1.56 0.0242 2.7
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with P300-measurement outside the period of heaviest use (n=116)
and users with P300-measurement during the period of heaviest use
(n=20). There was no significant association between cannabis use
and P300 (Coef=.712; 95%-CI: − .290 to 1.714; p=.163) and control-
ling for lifetime cannabis use did not reduce the association between
rs1045642 in ABCB1 and P300 amplitude (Coef=−1.469; 95%-CI:
−2.322 to − .616; p=.00079).
4. Discussion
Previous research, as reviewed by Turetsky (Turetsky et al., 2007)
and van der Stelt (van der Stelt and Belger, 2007), supports the reliability
of reduced P300 amplitude as intermediate phenotype for schizophrenia.
Nevertheless, the knowledge of the genetic underpinnings of P300 gen-
eration in schizophrenia is limited. This study examined a range of 193
candidate SNPs for their associationwith P300 amplitude in 336 patients
with schizophrenia.
Of the 193 selected SNPs, 4 SNPs showed potentially relevant associ-
ation with P300 amplitude at a significance level of pb .01, situated in
ABCB1, DISC-1, BDNF and MIR137. One of these SNPs, rs1045642 in
ABCB1, was most convincingly associated with P300 amplitude, while
there was modest evidence for rs1572899 in DISC-1 and rs6265 in
BDNF. The association between P300 amplitude and the novel
genome-wide supported risk variant rs1625579 in MIR137 was not
supported in the sensitivity analysis.
The ABCB1 finding is in line with the results of Liu and colleagues
(Liu et al., 2009), who used a parallel independent component anal-
ysis of electrophysiological and genetic data (384 SNPs) in order toFig. 1. Scatterplot of P300 amplitude over ABCB1-genotype. ° indicates average.investigate the genetic underpinnings of auditory ERP components
in a sample of healthy individuals. They found the exact same SNP
in ABCB1 (rs1045642), which encodes for P-glycoprotein, to be
associated with P300 amplitude. The fact that two studies in differ-
ent samples, one in healthy volunteers and one in patients with
schizophrenia, identify the same SNP from a set of hundreds of
markers at the Bonferroni-corrected threshold of significance,
makes it unlikely that this is a chance finding.
P-glycoprotein has a known function in ATP-driven cellular excretion
of, among others, drugs (Moons et al., 2011) and THC (Bonhomme-Faivre
et al., 2008). Although rs1045642 is a synonymous polymorphism, it
changes the substrate specificity of the translated protein (Kimchi-
Sarfaty et al., 2007) and can thus be considered functional. Little is
known about the specific influence of the polymorphism on the cellular
excretion of different substrates, like antipsychotic drugs and THC.
However, post-hoc analyses in the present study, controlling for type of
used antipsychotic drug, could not explain the association between
rs1045642 and P300 amplitude. This is in line with expectations, since
Liu et al. (2009) found the same genotype-phenotype association in
healthy individuals, free of antipsychotic drugs. Similarly, controlling for
cannabis did not reduce the association between rs1045642 in ABCB1
and P300 amplitude, indicating that the association is unlikely to be me-
diated by genetically determined differences in P-glycoprotein excretion
of THC. The underlying biology of the strong genotype-phenotype associ-
ation between rs1045642 and P300 amplitude, as well as the specific sig-
nificance for schizophrenia, remains to be elucidated.
Previous research on a balanced translocation implicated DISC1 in
P300 generation in schizophrenia (Blackwood et al., 2001), supported
by a recent study of common genetic variation in this gene (Shaikh etWhiskers indicate interval of 1 standard deviation under and above mean.
Table 3
Outcome parameters (regression coefficient (coef), standard-error (SE), p-value (p)
and 95%-confidence interval (95%-CI)) of a multiple regression model with P300 am-
plitude as dependent variable and dummy variables for each class of anti-psychotic
medication as independent variables. Number of patients taking each class of
anti-psychotics is indicated in the second column (n).
Class of anti-psychotic n coef SE p 95%-CI
Fenothiazines 21 −2.111 1.310 0.108 −4.691 to 0.470
Thioxanthenes 46 −1.577 0.969 0.105 −3.488 to 0.333
Butyrophenones 28 0.833 1.223 0.496 −1.576 to 3.242
Diphenylbutylpiperidine 2 – – – –
Amisulpride 22 1.995 1.507 0.187 −0.975 to 4.964
Aripiprazole 4 – – – –
Clozapine 25 0.246 1.433 0.864 −2.576 to 3.069
Olanzapine 76 −1.214 1.249 0.332 −3.675 to 1.247
Quetiapine 25 −1.139 1.540 0.460 −4.173 to 1.895
Risperidone 88 − .639 1.196 0.593 −2.996 to 1.717
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although it should be noted that the associated SNP in this study
(rs1572899) did not survive Bonferroni correction for multiple testing,
and is not in linkage disequilibriumwith rs821597, which was found to
be associated with P300 amplitude in the study of Shaikh et al. (2011).
Earlier research has also examined the role of rs6265, better known
as BDNF Val66Met, in P300 generation in the general population;
Schofield reported a slowed P300 response in Met-homozygotes
(Schofield et al., 2009), whereas Hansell failed to find an association be-
tween rs6265 and P300 amplitude (Hansell et al., 2007). In this study in
schizophrenia patients, the Met-allele was associated with a lower P300
amplitude, although not at the Bonferroni corrected threshold of
significance.
Rs1625579 is situated in an intron of a putative primary transcript
for microRNA 137 (MIR137), a regulator of neuronal maturation and
function. The recent GWAS of Ripke et al. suggested that MIR137
forms part of a newly detected etiological mechanism in schizophrenia
(Ripke et al., 2011). Unlike the three other SNPs with a p-valueb .01 in
the main analysis, the association between P300 amplitude and
rs1625579 was not confirmed in the sensitivity analysis.
Some limitations of this study are worth noting. Although consider-
able in the light of previous studies, the sample size of 336 patientswith
a psychotic disordermay have been underpowered to detect more sub-
tle genetic determinants of P300 generation. With the additional sensi-
tivity analysis in 191 patients, lower statistical power was partially
compensated by a gain of signal-to-noise ratio. Secondly, the lack of a
healthy control sample makes it impossible to draw inferences about
the specificity of the findings. However, since P300 is an important
intermediate phenotype of schizophrenia, every component explaining
some of the individual differences in P300 amplitude may be of signifi-
cance, as for example, P300 amplitude may help to predict transition in
subjects at high risk for developing psychosis (van Tricht et al., 2011).
Lastly, since the molecular pathway underlying P300 generation is not
fully known, the a priori SNP selection can be questioned. Therefore,
future work could use a genome-wide or candidate gene tag-SNP
approach to unravel the genetic underpinnings of the P300 generation,
but the sample of 336 patients was insufficiently powered to allow for
this strategy. Nevertheless, we would argue that the selection in this
study harborsmost of the relevant SNPs based on the available informa-
tion and includes SNPs from the classical candidate genes as well as
those from genome-wide studies.
Since P300 is one of themost established intermediate phenotypes of
schizophrenia, improving the efforts to unravel its genetic underpinnings
could be an interesting complementary strategy to increase our under-
standing of the genetic and biological mechanisms of this disorder.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.schres.2012.07.018.Role of funding source
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